Report
EUR 14.32 For Business Accounts Only

Thanks to a better fundamental star rating, YUHAN sees an upgrade to Neutral

The independent financial analyst theScreener just awarded an improved star rating to YUHAN (KR), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as moderately risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date February 11, 2022, the closing price was KRW 57,700.00 and its expected value was estimated at KRW 58,839.46.
Underlying
Yuhan Corporation

Yuhan is engaged in the research, development and manufacturing of pharmaceutical products. Co. provides non-prescription drugs such as vitamins, cosmetics, hair dyes, sanitary goods and animal remedies; and prescription drugs such as antibiotics, anti-platelet aggregation drugs, cold remedies, gastric ulcer remedies, hypertension drugs and diabetes drugs. Co. also provides household products such as bleaching agents, and animal drug products such as antimicrobials.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch